Alcon Yönetim

Yönetim kriter kontrolleri 4/4

Alcon CEO'su David Endicott, Jul2018 tarihinde atandı, in görev süresi 6.33 yıldır. in toplam yıllık tazminatı $ 12.33M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10.7% maaş ve 89.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.047% ine doğrudan sahiptir ve bu hisseler $ 20.04M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5 yıl ve 5.8 yıldır.

Anahtar bilgiler

David Endicott

İcra Kurulu Başkanı

US$12.3m

Toplam tazminat

CEO maaş yüzdesi	10.7%
CEO görev süresi	6.3yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	5yrs
Yönetim Kurulu ortalama görev süresi	5.8yrs

Son yönetim güncellemeleri

Recent updates

Alcon to acquire U.S. commercialization rights to ophthalmic eye drops Simbrinza from Novartis

Apr 28

Alcon: Global Leader In An Attractive End-Market

Dec 16

CEO Tazminat Analizi

David Endicott'un ücretlendirmesi Alcon'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$12m	US$1m	US$974m
Sep 30 2023	n/a	n/a	US$450m
Jun 30 2023	n/a	n/a	US$362m
Mar 31 2023	n/a	n/a	US$341m
Dec 31 2022	US$10m	US$1m	US$335m
Sep 30 2022	n/a	n/a	US$571m
Jun 30 2022	n/a	n/a	US$457m
Mar 31 2022	n/a	n/a	US$460m
Dec 31 2021	US$11m	US$1m	US$376m
Sep 30 2021	n/a	n/a	US$332m
Jun 30 2021	n/a	n/a	US$183m
Mar 31 2021	n/a	n/a	-US$390m
Dec 31 2020	US$8m	US$1m	-US$531m
Sep 30 2020	n/a	n/a	-US$717m
Jun 30 2020	n/a	n/a	-US$636m
Mar 31 2020	n/a	n/a	-US$604m
Dec 31 2019	US$7m	US$1m	-US$656m

Tazminat ve Piyasa: David 'ın toplam tazminatı ($USD 12.33M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 12.67M ).

Tazminat ve Kazançlar: David 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

David Endicott (59 yo)

6.3yrs

Görev süresi

US$12,325,391

Tazminat

Mr. David J. Endicott is President and Chief Executive Officer at Aerie Pharmaceuticals, Inc. since November 21, 2022. He had been the Chief Executive Officer of Alcon, Inc. since July 1, 2018. He is the C...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% $ 4.8m
David Endicott	CEO & Director	6.3yrs	US$12.33m	0.047% $ 20.0m
Arthur Cummings	Executive Director	no data	US$284.68k	0.0012% $ 497.8k
Timothy Stonesifer	Chief Financial Officer	5.6yrs	Veri yok	0.020% $ 8.3m
Ian Bell	Senior VP & COO	less than a year	Veri yok	0.0081% $ 3.5m
Margaret Buckley	Chief Accounting Officer	no data	Veri yok	Veri yok
Franck Leveiller	Senior VP	2.4yrs	Veri yok	Veri yok
Royce Bedward	Senior VP	no data	Veri yok	Veri yok
Kimberly Martin	Senior VP	4.3yrs	Veri yok	Veri yok
Laurent Attias	Head of Corporate Development	no data	Veri yok	0.0040% $ 1.7m
Leon Sergio Fraustro	President of North America	9.3yrs	Veri yok	0.0043% $ 1.8m
Ed McGough	Senior VP and Head of Global Manufacturing & Technical Operations	no data	US$2.03m	Veri yok

5.0yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: ALC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
F. Ball	Executive Chairman	5.8yrs	US$1.17m	0.011% $ 4.8m
David Endicott	CEO & Director	5.8yrs	US$12.33m	0.047% $ 20.0m
Arthur Cummings	Executive Director	5.8yrs	US$284.68k	0.0012% $ 497.8k
Karen May	Independent Director	5.8yrs	US$325.52k	0.0052% $ 2.2m
D. Grossman	Independent Vice Chair	5.8yrs	US$361.69k	0.0031% $ 1.3m
Thomas Glanzmann	Independent Director	5.8yrs	US$352.98k	0.0041% $ 1.8m
Dieter Spälti	Independent Director	5.8yrs	US$236.83k	0.0049% $ 2.1m
Scott Maw	Independent Director	5.8yrs	US$333.87k	0.0031% $ 1.3m
Lynn Bleil	Independent Director	5.8yrs	US$296.31k	0.0019% $ 829.7k
Ines Pöschel	Independent Director	5.8yrs	US$293.86k	0.0021% $ 902.1k
RaQuel Bono	Independent Director	2.6yrs	US$256.66k	0.00056% $ 238.3k

5.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.8 yıldır).

Alcon Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Alcon Announces Management Changes

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc., Annual General Meeting, May 05, 2023

Insufficient new directors

Insufficient new directors

Alcon Inc., Annual General Meeting, Apr 28, 2021

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Earnings Guidance for the Year 2024

Alcon Announces the U.S. Launch of PRECISION®, the Only One-Week Replacement Contact Lens

Alcon Q2: Positive News From Unity VCS/CS And AR-15512

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Alcon Inc. Maintains Earnings Guidance for the Year 2024

Now 21% undervalued

Alcon: Trading At An Undeserved Premium Valuation

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

First quarter 2024 earnings: EPS exceeds analyst expectations

Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)

Upcoming dividend of CHF0.16 per share

Alcon Inc. Approves Gross Dividend

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Alcon Announces Management Changes

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

Dividend of CHF0.16 announced

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

Alcon: Lackluster Growth Given Its Valuation

Alcon: The Steady Force Of 'Boring'

Price target increased by 8.4% to US$85.32

Price target increased by 7.9% to US$84.07

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.14 per share at 0.3% yield

Full year 2022 earnings: EPS misses analyst expectations

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon reached $199M settlement with J&J Surgical Vision

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Alcon: Case Of Growth Destructive To Value, Reiterate Hold At 24x Earnings

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon a buy at Mizuho on 'eyecare dominance'

Alcon Inc. Updates Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Q3 2022 Earnings Preview

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon: Looking To Break Downtrend Before Entry

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Alcon downgraded to hold at Societe Generale on macro headwinds

Second quarter 2022 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Revenue Guidance for 2022

Alcon: Revisiting The Investment Thesis

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Upcoming dividend of CHF0.13 per share

The Recent Pullback Makes Alcon More Attractive

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Full year 2021 earnings: EPS exceeds analyst expectations

Alcon Inc. Proposes Dividend

Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe